Immunology companies study and manipulate the immune system to develop therapies, diagnostics and research tools. The field plays a central role in areas such as cancer, infectious disease, autoimmune disorders and vaccine development.
This category includes companies working on:
Browse 182 UK immunology companies below.
Virus-like particle therapeutics for chronic inflammatory skin conditions
Glen Clova Scientific is a biotechnology company developing active biologic drugs for chronic inflammatory and autoimmune disorders, with an initial focus on immuno-dermatology. Its proprietary virus-like particle platform is designed to induce targeted immune responses against self-produced proteins that drive…
Integrated CRO services from drug discovery to manufacture
Charles River Laboratories is a global contract research organisation providing integrated preclinical drug discovery and development services to pharmaceutical, biotechnology and academic clients. UK operations span multiple sites offering medicinal chemistry, biology, ADME/PK, structural biology, immunology, in vivo…
ADC oncology company developing novel spliceosome-modulating payloads
Akari Therapeutics is a clinical-stage biopharma company developing next-generation bi-functional antibody-drug conjugates for cancer treatment. Its proprietary ADC platform centres on PH1, a novel spliceosome-modulating small molecule payload designed to disrupt RNA splicing in tumour cells and activate anti-tumour…
Immunotherapeutics targeting drug-resistant bacterial infections
Centauri Therapeutics is a clinical-stage immunotherapy company developing treatments for life-threatening infectious diseases using its proprietary platform. The technology uses synthetic bifunctional molecules that recruit and redirect naturally occurring anti-glycan antibodies to target pathogens, engaging both…
CAR-T and bispecific antibody therapies for blood cancers
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for haematological malignancies and autoimmune diseases. Its lead asset, HG-CT-1, is a third-generation anti-FLT3 CAR-T cell therapy for relapsed and refractory acute myeloid leukaemia, currently in a Phase 1…
Global biopharma with UK R&D centre on the Wirral Peninsula
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company with a long-established UK R&D site at Moreton on the Wirral Peninsula and its UK and Ireland commercial headquarters in Uxbridge. The Moreton facility, expanded in 2025, conducts chemistry, manufacturing and control activities supporting pharmaceutical…
Veterinary ELISA diagnostic kits and immunoassay reagents
MV Diagnostics develops and supplies veterinary immunodiagnostic kits and laboratory reagents for animal disease testing. Its product portfolio includes ELISA assays, recombinant proteins and peptides used in research and veterinary diagnostic laboratories. The company develops immunoassays and multiplex testing…
Engineered hybrid interferon therapeutics for viral and immune-mediated disease
ILC Therapeutics is a pre-clinical biotechnology company developing hybrid interferons, an engineered cytokine drug class combining favourable attributes of multiple naturally occurring interferon subtypes. The platform rationally designs novel candidates with reduced toxicity and pleiotropic activity across multiple…
Allogeneic neutrophil cell therapy platform for solid tumours
LIfT BioSciences is a biotechnology company developing a first-in-class allogeneic neutrophil immunotherapy for the treatment of solid tumours. Its platform produces Immuno-Modulatory Alpha Neutrophils (IMANs) from donor haematopoietic or induced pluripotent stem cells using a proprietary enhancement process. IMANs…
Inorganic nanoscale immune modulators for infection, cancer and autoimmunity
Iuvantium is a biotechnology company developing therapeutics and vaccines based on inorganic nanoscale materials that modulate the immune system. The company uses tailored inorganic probes to study how the immune system responds, builds a computational model of immune behaviour, and designs programmable immune…
In vivo immune cell reprogramming for autoimmune and inflammatory disease
Flip Therapeutics is a biotechnology company developing in vivo immune cell engineering therapies for chronic autoimmune and inflammatory diseases, including multiple sclerosis, type 1 diabetes and inflammatory bowel disease. The company reprograms pathogenic T cells into homeostatic, anti-inflammatory cells directly…
Phase 3 urcosimod therapy for neuropathic corneal pain
OKYO Pharma is a clinical-stage biopharmaceutical company developing topical therapies for neuropathic corneal pain and other ocular surface conditions. Its lead candidate, urcosimod (formerly OK-101), is a chemerin receptor agonist designed to modulate inflammation and corneal pain signalling. Phase 2a testing…
Oral microbiome therapeutics for gastrointestinal and hepatic disease
EnteroBiotix is a clinical-stage biopharmaceutical company developing orally delivered, full-spectrum microbiome therapeutics for diseases linked to gut microbiome disruption. Its lead asset EBX-102-02 demonstrated clinically meaningful improvements in irritable bowel syndrome in Phase 2a trials, with a Phase 2b study…
Engineered biologics with conditional activation for precision cancer immunotherapy
Switch Biologics is a UK biotechnology company developing engineered protein biologics for cancer immunotherapy. The company applies directed evolution and protein engineering to build conditionally activated therapeutics that respond to two simultaneous molecular signals, a design intended to concentrate activity…
GPCR-targeted small molecule therapeutics
Liminal BioSciences is a development-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate G protein-coupled receptor pathways. The company targets metabolic, inflammatory, and fibrotic diseases using an integrated drug discovery platform combining…
Small molecule drug discovery platform focused on immuno-inflammation
C4X Discovery (C4XD) is a UK drug discovery company developing small molecule drug candidates using its proprietary computational and structural chemistry platform. It applies enhanced candidate molecule design and patient stratification capabilities to generate drug candidates across immuno-inflammatory disease…
Needle-free solid dose vaccine formulation and delivery platform
aVaxMed Limited is a UK biotech developing the aVaxziPen platform, a proprietary needle-free, thermally stable, solid dose vaccine delivery system. The technology encapsulates vaccine antigens into unit solid doses administered via a pen applicator, removing the need for needles and reducing cold chain requirements.…
Engineered T-regulatory cell therapies for immune-mediated diseases
Quell Therapeutics is a clinical-stage UK biotech developing engineered T-regulatory (Treg) cell therapies for immune-mediated diseases, using its proprietary technology to engineer Tregs with enhanced persistence and potency. Its lead candidate QEL-001 is in the Phase 1/2 LIBERATE trial for liver transplant…
IVD manufacturer serving clinical laboratory and transfusion medicine
QuidelOrtho is a global in vitro diagnostics company with a major UK manufacturing and development facility in Pencoed, Wales, employing over 600 people. The site produces immunohematology reagents for transfusion medicine and immunoassay products covering infectious disease, endocrinology, and oncology testing,…
Breast milk microbiome biotech developing infant health solutions
BoobyBiome Ltd is a biotechnology company developing products to give formula-fed and high-risk infants access to the beneficial microbiome of breast milk. Its platform is built on the world's first high-resolution breast milk microbiome database and a proprietary biobank of strains from hundreds of donor samples. Its…